A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis

Summary

This is an open-label, sequential cohorts, flexible dose study to evaluate the tolerability, safety and pharmacokinetics of iloperidone in elderly patients with Parkinson's disease psychosis (PDP).

Timeline

Start

2022-06

Primary completion

2023-11

Completion

2023-11

Outcome

Outcome not reported

Stopped (Business): “Study was terminated for business reasons; not due to safety or efficacy concerns.”

Drugs

Indications